Development of oral therapy for type 1 diabetes mellitus
| Project/Area Number |
24791093
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Setsunan University |
|---|
Principal Investigator |
TSUJI Takumi 摂南大学, 薬学部, 講師 (90454652)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | FTY720 / １型糖尿病 / DPP-4阻害薬 / 免疫学 / 糖尿病 |
|---|
| Research Abstract |
The therapeutic effectiveness against type 1 diabetes mellitus of a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, was examined in the non-obese diabetic (NOD) mouse model. In this study, we tried to develop criteria to identify those individuals for whom this combination therapy would be appropriate. In the result, combination therapy with FTY720 and sitagliptin is a promising candidate for type 1 diabetes mellitus treatment, and it might be important to initiate treatment at less than 200 mg/dL of the fasting-blood glucose level.
|
Report
(3 results)
Research Products
(10 results)
-
[Journal Article] Oral therapy for type 1 diabetes mellitus using a novel immunomodulater, FTY720 (Fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, examined in non-obese diabetic(NOD) mice2012
Author(s)
Tsuji, T., Yoshida, Y., Fujita, T., Kohno, T
-
Journal Title
J. Diab. Invest
Volume: 3(5)
Pages: 441-448
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
